Simultaneous Presentation of Wilson’s Disease and Autoimmune Hepatitis: A Case Report and Review of Literature

Naghi Dara 1; Farid Imanzadeh 1; Ali Akbar Sayyari 1; Peiman Nasri 1; Amir Hossein Hosseini 1, *

1 Department of Pediatric Gastroenterology, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran

*Corresponding Author: Amir Hossein Hosseini, Department of Pediatric Gastroenterology, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran. Tel: +98-9128887347, Fax: +98-2122590004, E-mail: ah_hosseini@sbmu.ac.ir

Received: April 5, 2015; Revised: April 20, 2015; Accepted: April 28, 2015

1. Introduction

Wilson’s disease (WD) and autoimmune hepatitis (AIH) are considered as the common causes of acute and chronic hepatitis. The coexistence of these diseases in one patient, at the same time, is rare. Hepatocyte necrosis and intracellular antigen exposure to immune system is seen in WD and results in low titer autoantibody production. This finding is a misleading point in differentiating AIH from WD (1). In this group of patients, there is no evidence of dermatologic manifestations of autoimmune disorders and the serum level of immunoglobulins is not elevated. On the other hand, there are several cases of WD that were initially diagnosed as AIH. A high percentage of patients diagnosed with AIH and partial response to steroids and azathioprine was achieved in these patients. Therefore, it is highly recommended to screen WD patients labeled as AIH and partial response to steroids and azathioprine was achieved in these patients. This finding is a misleading point in differentiating AIH from WD (1). In this group of patients, there is no evidence of dermatologic manifestations of autoimmune disorders and the serum level of immunoglobulins is not elevated. On the other hand, there are several cases of WD that were initially diagnosed as AIH and partial response to steroids and azathioprine was achieved in these patients. Therefore, it is highly recommended to screen WD patients labeled as AIH, especially when there is poor response to immunosuppressive treatments. In this situation, combined treatment with steroid and d-penicillamine may be effective (2). Here, we present a case of acute hepatitis with dominant features of both WD and AIH.

2. Case Presentation

A 10-year-old boy presented to our tertiary children hospital with a history of nausea, vomiting, and tea-color urine, since 1 day before admission. His parents were not relatives.
Liver span was about 120 mm, on ultrasonography, with no space-occupying lesion and homogenous echo pattern parenchyma. Spleen size was in the upper limit of normal, with normal parenchyma. Hydrops of gallbladder was seen. In slit-lamp examination by ophthalmologist, the Kayser-Fleischer ring was seen in upper and lower parts of cornea. Finally, liver biopsy was performed and histopathologic studies revealed fibrous bands encircling clusters of hepatocytes and regenerative nodules. Moderate to severe lymphocyte infiltrations and mild infiltration of eosinophil and neutrophils resulted in interface hepatitis. Binuclear and multi-nuclear hepatocytes were seen, with feathery degeneration in several cells. In specific staining of tissue, no finding in favor of copper rich cells was seen. Histochemical analysis with rhodamine and orcein was negative (Figures 1 and 2). However, the amount of copper in dry liver tissue was about 20 times the upper limit of normal. Scoring system for this patient was done and the score of 7 was reached for him, in both of WD and AIH scoring systems [according to the international scoring system, the score ≥ 7 are diagnostic for AIH and the score > 4 is considered positive for WD (3, 4)].
By considering concomitant WD and AIH, we started oral prednisolone (1 mg/Kg/day) and azathioprine (1 mg/kg) and d-penicillamine for the patient, and an acceptable response was reached. Liver enzymes declined dramatically, after 20 days of treatment, and changed to near normal levels, after 6 months of medical therapy (aspartate transaminase = 54 mg/dL and alanine transferase = 57 mg/dL). Prothrombin time and international normalization ratio changed to 17.5 seconds and 1.6, respectively, after administration of treatment and, at the end of 6 months of treatment, they were 14 seconds and 1.23, respectively. Also, the total and direct bilirubin changed to 0.7 and 0.2 mg/dL, at 6 months.

3. Discussion

Acute hepatitis has a wide variety of etiologies. Therefore, the correct diagnosis and selecting the appropriate therapy remains a clinical dilemma that pediatric gastroenterologists are faced in their practice with it (3, 5). There are few cases with classical manifestations of WD, or several features of AIH, simultaneously. In this group of patients with WD, more convincing features of AIH are present and initial treatment with immunosuppressive medication may result in relative improvement (2). Differentiating these two entities is important. Autoantibody can be positive in WD due to hepatocyte necrosis, especially in early stage of this disease. Liver biopsy and histochemical staining is another diagnostic modality. Histochemical stains for copper or copper-associated proteins, such as rhodamine, provide qualitative evidence of increased liver copper (6). However, despite elevated hepatic copper content, these stains are frequently negative in patients with WD. Another test, which is confirmatory in patients with WD, is the 24-hour urine copper. This test is abnormal in 80 - 85% of untreated patients with WD. However, in any severe icteric hepatitis, abnormal copper metabolism may occur. Although the 24-hour urine copper in acute icteric hepatitis is occasionally increased, the level does not exceed the value of 200 microgram/24 hour (7, 8). In relation to a certain degree of overlapping between these two entities, it is highly recommended to screen for WD, particularly when poor response to steroid treatment is seen in patients with AIH (2, 9, 10). On the other hand, there are several cases of WD patients, who are suffering from superimposed manifestations of AIH. In this group of patients, combination therapy with penicillamine and steroid may be of benefit (1, 6). The coexistence of WD and AIH is not the sole example of concomitant presentation of two diseases (7). There are several other situations where the coexistence of two hepatic diseases in the same patient, at the same time, has been reported in the literature. The other example on this issue is the simultaneous presentation of AIH and concomitant non-alcoholic fatty liver disease (NAFLD) (11). Steroids, as the mainstay of treatment in AIH, can result in insulin resistance, obesity, and fatty liver. This predisposes these patients to NAFLD. On the other hand, the incidence of obesity and NAFLD, as its complication, is increasing in the general population. Therefore, it is reasonable to investigate AIH associated with NAFLD, before starting therapy. Liver biopsy is the gold standard the case (12).

The observation of this young patient, in our practice, and the thorough review of the literature lead to the conclusion that physicians should consider coexistence of
WD and AIH in patients with several difficulties in establishing the correct diagnosis. Although the coexistence of WD and AIH is rare, we need to maintain a high level of awareness of this problem. Therefore, it is reasonable to consider this type of hepatitis in rare patients with dominant features of the diseases, at the same time, and start medical therapy for both of them.

Authors’ Contributions

Acquisition of data: Peiman Nasri. Drafting of the manuscript: Amir Hossein Hosseini. Critical revision of the manuscript for important intellectual content: Farid Imanzadeh, Naghi Dara, Peiman Nasri, Amir Hossein Hosseini. Administrative, technical, and material support: Ali Akbar Sayyari. Study supervision: Farid Imanzadeh.

References

1. Yener S, Akarsu M, Karacanci C, Sengul B, Topalak O, Biberoglu K, et al. Wilson’s disease with coexisting autoimmune hepatitis. J Gastroenterol Hepatol. 2004;19(1):114–6.
2. Milkiewicz P, Sakena S, Hubscher SG, Elias E. Wilson’s disease with superimposed autoimmune features: report of two cases and review. J Gastroenterol Hepatol. 2000;15(5):570–4.
3. Roberts EA, Schilsky MI. American Association for Study of Liver D. Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47(6):2089–93.
4. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008;48(3):699–706.
5. Halimi A, Ghadamily P, Afshar SE, Moussavi F, Hosseini AH. A Neglected Case of Wilson Disease. J Compr Ped. 2013;4(3):143–6.
6. Scheinberg IH, Sternlieb I. Wilson’s Disease. Philadelphia, PA: Saunders; 1964.
7. Deutsch M, Emmanuel T, Koskinas J. Autoimmune Hepatitis or Wilson’s Disease, a Clinical Dilemma. Hepat Mon. 2013;13(5):e7872.
8. Singh V, Bhattacharyya SK, Sunder S, Kachhawaha JS. Serum and urinary copper in acute hepatic encephalopathy. J Assoc Physicians India. 1990;38(7):467–9.
9. Santos KG, Alissa F, Reyes J, Teot L, Ameen N. Fulminant hepatic failure: Wilson’s disease or autoimmune hepatitis? Implications for transplantation. Pediatr Transplant. 2005;9(1):312–6.
10. Wozniak M, Socha P. Two cases of Wilson disease diagnosed as autoimmune hepatitis. Przegl Epidemiol. 2002;56 Suppl 5:222–5.
11. Jamali R. Inappropriate Long-Term Steroid Therapy in Autoimmune Hepatitis Might Cause the Development of Non-Alcoholic Fatty Liver Disease: A Challenging Situation. Thrita J of Med Sci. 2012;1(4):11–2.
12. Shafiei M, Alavian SM. Autoimmune hepatitis in Iran: what we know, what we don’t know and requirements for better management. Hepat Mon. 2012;12(2):73–6.